Team:Warwick
From 2014.igem.org
(Difference between revisions)
Line 127: | Line 127: | ||
<tr> | <tr> | ||
<td width="45%" valign="top"> | <td width="45%" valign="top"> | ||
- | |||
Line 137: | Line 136: | ||
Our project involves the production of a self-replicating RNA system, utilizing the well characterized Hepatitis C virus subtype 1b RNA dependent RNA polymerase (RdRp). By using a number of different biological components, We wish to develop a system whereby small interfering RNAs (siRNAs) are produced intermittently; without having the need to systematically introduce siRNAs through injectable delievery into patients. As we circumvent the biological flow of information at the level of mRNA, our system overcomes the limitation of gene therapeutic methods which utilize vectors that routinely integrate into the host genome and can downregulate, or activate genes | Our project involves the production of a self-replicating RNA system, utilizing the well characterized Hepatitis C virus subtype 1b RNA dependent RNA polymerase (RdRp). By using a number of different biological components, We wish to develop a system whereby small interfering RNAs (siRNAs) are produced intermittently; without having the need to systematically introduce siRNAs through injectable delievery into patients. As we circumvent the biological flow of information at the level of mRNA, our system overcomes the limitation of gene therapeutic methods which utilize vectors that routinely integrate into the host genome and can downregulate, or activate genes | ||
+ | |||
+ | |||
+ | |||
+ | <div style="text-align: 700"><img src="https://static.igem.org/mediawiki/2014/8/8b/RISC.png" width="3500" height="3000" /></div> | ||
Revision as of 11:23, 1 August 2014